Please login to the form below

Not currently logged in
Email:
Password:

Neuraceq

This page shows the latest Neuraceq news and features for those working in and with pharma, biotech and healthcare.

EMA unveils draft guidelines for Alzheimer’s disease research

EMA unveils draft guidelines for Alzheimer’s disease research

Although the last few years have seen a number of Alzeimer's diagnostics approved, among them GE Healthcare Vizamyl (flutemetamol) and Piramal's Neuraceq (florbetaben F18), research progress for a treatment

Latest news

  • CHMP backs Piramal's Alzheimer's imaging agent CHMP backs Piramal's Alzheimer's imaging agent

    Neuraceq recommended for approval in Europe. Piramal is close to winning EU approval for its Alzheimer's disease (AD) diagnostic Neuraceq after a positive opinion from the EMA's Committee for ... Piramal acquired rights to Neuraceq from Bayer in 2012,

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics